Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer
HPB · 2025
DOI: 10.1016/j.hpb.2025.02.002 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift HPB, 2025. Verfasst von Leonoor V Wismans und 8 weiteren Autor:innen. Beteiligte Einrichtung: Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Pulmonology, Erasmus MC, University Medi…. Hauptthemen laut MEDLINE: Antibodies, Viral, Carcinoma, Pancreatic Ductal, COVID-19 Vaccines, Immunogenicity, Vaccine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Patients with pancreatic ductal adenocarcinoma (PDAC) are at increased risk for severe COVID-19. Although COVID-19 vaccines are highly recommended for this population, studies on immunogenicity are lacking. We aimed to investigate the immunogenicity of COVID-19 vaccines in PDAC patients, compared to controls. METHODS: This observational study evaluated SARS-CoV-2 spike-specific IgG (S-IgG) levels after priming and booster vaccination in PDAC patients. Primary outcomes were seroprevalence and S-IgG levels compared to matched controls. Secondary outcomes included safety and the association of S-IgG levels with clinical and therapeutic characteristics. RESULTS: In 81 PDAC patients, a total of 86 matched S-IgG levels were available (33 post-priming; 53 post-booster). After priming, 88% (29/33) of PDAC patients were seropositive compared to 97% (32/33) of controls (P=0.16). After booster, seropositivity increased to 98% (52/53) in PDAC patients and to 53/53 (100%) in controls (P=0.31). Patients with active disease during booster vaccination had significantly lower S-IgG levels compared to patients with a history of PDAC (P=0.002). Cancer therapies were not associated with distinct S-IgG levels (P>0.05). No serious adverse events occurred. CONCLUSION: Priming and booster COVID-19 vaccines are safe and immunogenic in PDAC patients, comparable to controls. The antibody response was effectively increased by the booster vaccination and not impaired by cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Pulmonology, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Surgery, Erasmus…
- Department of Viroscience, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
- Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Pulmonology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
- Erasmus MC Cancer Institute, Erasmus MC, University Medical Center Rotterdam, the Netherlands; Department of Surgery, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
- Department of Pulmonology, Erasmus MC, University Medical Center Rotterdam, the Netherlands.
Zitieren
APA
Wismans, L. V., de Vries, R. D., van Eijck, C. W. F., Verheij, M., Bogers, S., Aerts, J. G. J. V., GeurtsvanKessel, C. H., van Eijck, C. H. J., & van der Eijk, A. A. (2025). Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. HPB. https://doi.org/10.1016/j.hpb.2025.02.002
Vancouver
Wismans LV, de Vries RD, van Eijck CWF, Verheij M, Bogers S, Aerts JGJV, et al. Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer. HPB. 2025. doi:10.1016/j.hpb.2025.02.002
BibTeX
@article{Wismans2025,
author = {Wismans, Leonoor V and de Vries, Rory D and van Eijck, Casper W F and Verheij, Maaike and Bogers, Susanne and Aerts, Joachim G J V and GeurtsvanKessel, Corine H and van Eijck, Casper H J and van der Eijk, Annemiek A},
title = {Immunogenicity and safety of COVID-19 vaccines in patients with pancreatic cancer},
journal = {HPB},
year = {2025},
doi = {10.1016/j.hpb.2025.02.002}
}
EUVIMED